Investment Analysts’ Weekly Ratings Updates for Teva Pharmaceutical Industries Limited (TEVA)

A number of firms have modified their ratings and price targets on shares of Teva Pharmaceutical Industries Limited (NYSE: TEVA) recently:

  • 10/20/2017 – Teva Pharmaceutical Industries Limited was given a new $19.00 price target on by analysts at Barclays PLC. They now have a “hold” rating on the stock.
  • 10/20/2017 – Teva Pharmaceutical Industries Limited was given a new $15.00 price target on by analysts at Royal Bank Of Canada. They now have a “sell” rating on the stock.
  • 10/19/2017 – Teva Pharmaceutical Industries Limited was given a new $17.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock.
  • 10/13/2017 – Teva Pharmaceutical Industries Limited was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 10/6/2017 – Teva Pharmaceutical Industries Limited was given a new $23.00 price target on by analysts at Piper Jaffray Companies. They now have a “hold” rating on the stock.
  • 10/5/2017 – Teva Pharmaceutical Industries Limited had its “market perform” rating reaffirmed by analysts at Wells Fargo & Company.
  • 10/5/2017 – Teva Pharmaceutical Industries Limited was given a new $15.00 price target on by analysts at Morgan Stanley. They now have an “underweight” rating on the stock.
  • 10/4/2017 – Teva Pharmaceutical Industries Limited was given a new $20.00 price target on by analysts at Wells Fargo & Company. They now have a “hold” rating on the stock.
  • 10/4/2017 – Teva Pharmaceutical Industries Limited had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $24.00 price target on the stock.
  • 10/4/2017 – Teva Pharmaceutical Industries Limited was given a new $21.00 price target on by analysts at Barclays PLC. They now have an “equal weight” rating on the stock.
  • 10/4/2017 – Teva Pharmaceutical Industries Limited had its “hold” rating reaffirmed by analysts at Mizuho. They now have a $16.00 price target on the stock.
  • 10/4/2017 – Teva Pharmaceutical Industries Limited had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
  • 10/4/2017 – Teva Pharmaceutical Industries Limited was upgraded by analysts at Zacks Investment Research from a “strong sell” rating to a “hold” rating. According to Zacks, “Pricing erosion in the U.S. generics business and the continued deterioration in Venezuela is hurting sales at Teva which led to a guidance and dividend cut in August. Teva is facing several other challenges in the form of generic competition for Copaxone, new competition for branded products and a high cost base and debt load. Also, Teva’s shares underperformed the generic industry this year so far. Nonetheless, Teva is progressing with its branded/generics drugs pipeline and is looking to strengthen its biosimilar pipeline. The Actavis Generics acquisition is contributing to growth of the Generics unit. Meanwhile, Teva is focusing on cost cutting and divestments to boost growth. However, a clear path to growth is not visible. Estimates have declined ahead of the company’s Q3 earnings release. The company also has a negative record of earnings surprises in recent quarters.”
  • 10/4/2017 – Teva Pharmaceutical Industries Limited had its “hold” rating reaffirmed by analysts at Maxim Group. They wrote, “Shares of TEVA are under pressure in the wake of the FDA’s approval of Mylan’s ANDA for generic copaxone 3x/week & 20 mg/ml QD injection. Teva has a press release estimating the impact of the two launches to its 4Q earnings of at least $0.25. Our estimates are under review but our Hold remaining remains in-effect. We had anticipated generic copaxone (3x) but not until 2018.””
  • 10/4/2017 – Teva Pharmaceutical Industries Limited had its “market perform” rating reaffirmed by analysts at Cowen and Company. They now have a $18.00 price target on the stock, down previously from $30.00.
  • 10/2/2017 – Teva Pharmaceutical Industries Limited was given a new $17.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock.
  • 10/2/2017 – Teva Pharmaceutical Industries Limited was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 9/28/2017 – Teva Pharmaceutical Industries Limited was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 9/21/2017 – Teva Pharmaceutical Industries Limited had its price target lowered by analysts at Sanford C. Bernstein from $28.00 to $20.00. They now have a “market perform” rating on the stock.
  • 9/21/2017 – Teva Pharmaceutical Industries Limited was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 9/18/2017 – Teva Pharmaceutical Industries Limited had its price target lowered by analysts at Royal Bank Of Canada from $21.00 to $15.00. They now have an “underperform” rating on the stock.
  • 9/18/2017 – Teva Pharmaceutical Industries Limited had its “hold” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $17.00 price target on the stock.
  • 9/14/2017 – Teva Pharmaceutical Industries Limited had its “neutral” rating reaffirmed by analysts at UBS AG. They now have a $19.00 price target on the stock.
  • 9/14/2017 – Teva Pharmaceutical Industries Limited had its “hold” rating reaffirmed by analysts at Maxim Group. They now have a $15.50 price target on the stock.
  • 9/13/2017 – Teva Pharmaceutical Industries Limited was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 9/13/2017 – Teva Pharmaceutical Industries Limited had its “buy” rating reaffirmed by analysts at Gabelli.
  • 9/12/2017 – Teva Pharmaceutical Industries Limited had its price target lowered by analysts at Jefferies Group LLC from $21.00 to $18.50. They now have a “hold” rating on the stock.
  • 9/11/2017 – Teva Pharmaceutical Industries Limited had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
  • 9/11/2017 – Teva Pharmaceutical Industries Limited was upgraded by analysts at BTIG Research from a “neutral” rating to a “buy” rating. They now have a $24.00 price target on the stock.
  • 9/11/2017 – Teva Pharmaceutical Industries Limited was given a new $17.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock.
  • 9/6/2017 – Teva Pharmaceutical Industries Limited had its price target raised by analysts at JMP Securities from $13.00 to $14.00. They now have an “underperform” rating on the stock.
  • 9/5/2017 – Teva Pharmaceutical Industries Limited had its “neutral” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $27.00 price target on the stock.
  • 9/5/2017 – Teva Pharmaceutical Industries Limited had its “underperform” rating reaffirmed by analysts at Royal Bank Of Canada.
  • 9/1/2017 – Teva Pharmaceutical Industries Limited was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 8/31/2017 – Teva Pharmaceutical Industries Limited had its “neutral” rating reaffirmed by analysts at Goldman Sachs Group, Inc. (The). They now have a $21.00 price target on the stock, down previously from $28.00.
  • 8/30/2017 – Teva Pharmaceutical Industries Limited had its “hold” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $27.00 price target on the stock.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) opened at 14.28 on Wednesday. The company has a 50 day moving average price of $16.47 and a 200-day moving average price of $25.16. Teva Pharmaceutical Industries Limited has a 52-week low of $14.20 and a 52-week high of $44.26. The firm’s market cap is $14.51 billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.07). The firm had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The company’s revenue was up 12.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.25 EPS. Equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.24 EPS for the current year.

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2017 Ticker Report. Google+.